+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-01-24Number of Pages: 152

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market (Marker Type - Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, and Oxidative Stress Biomarkers; End User - Contract Research Organizations (CRO) and Pharmaceutical Industry, Academic Research Institute, Hospitals, and Diagnostic Laboratories) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global NASH Biomarkers Market: Snapshot

Non-alcoholic Steatohepatitis (NASH) is a degenerative form of non-alcoholic fatty liver disease (NAFLD) that leads to damage and inflammation over time. The unwanted fat deposition in liver is the main cause of this disease.  If left untreated or undiagnosed, it can lead to liver cirrhosis and eventually progress to liver failure. The high prevalence of liver-related diseases has coaxed several industry players and research institutes to invest in development of sophisticated NASH diagnostic and therapeutic products. Owing to these reasons, the global NASH biomarkers is expected to reach a valuation of US$1.7 bn by the end of 2024 from US$201.2 mn in 2016. During the forecast period of 2016 and 2024, the global market is estimated to progress at a CAGR of 31.7%.

non alcoholic steatohepatitis biomarkers market

Increasing Number of Type 2 Diabetics to Augment Demand for NASH Biomarkers

Currently, histopathology using a liver biopsy which is an invasive method, imaging techniques like magnetic resonance imaging (MRI), transient Elastography (TE), ultrasound, etc., and in vitro diagnostic techniques using some biomarkers are used for diagnosing and monitoring NASH. However, the introduction of biomarkers has given the patients the option of non-invasive methods for understanding the stage and development of the disease. This precise factor is estimated to boost the market’s growth in the coming years. Analysts anticipate that the global market will also be driven by the huge untapped need for diagnosing NASH. Furthermore, the growing number of type 2 diabetics are also expected to augment the demand for NASH biomarkers as they are prone to liver-related diseases. Changing lifestyles and improving healthcare expenditure is also likely to make a significant difference to the soaring revenue of the overall market.

Serum Biomarkers to Lead the Pack during Forecast Period

On the basis of type, the global NASH biomarkers market is segmented into serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, and oxidative stress biomarkers. Of these, serum biomarkers and hepatic biomarkers are extensively used in the medical field. The serum biomarkers are expected to lead the global market due to ability to deliver efficient results. Apoptosis markers follow this lead closely. In terms of end users, the global NASH biomarkers market is segmented into CRO and pharmaceutical industries, academic research institutes, hospitals, and diagnostic laboratories. The report suggests that hospitals and diagnostic laboratories are likely to dominate the global market in the coming years. The increasing demand for non-invasive NASH diagnostic and monitoring tools in the ongoing trials by CRO and pharmaceutical manufacturers are expected to boost the share of the respective segment over the forecast period as well.

Increasing Number of Patients with NAFLD and NASH keep Europe in Lead

In terms of geography, the global NASH biomarkers market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Presently, Europe leads the pack due to the strong presence of players in the region. The report states that Europe will continue to dominate the global market due to the increasing pool of population suffering from NAFLD and NASH. Over the same period, North America will also show steady demand for NASH biomarkers due to its well-established healthcare industry and a huge population base.

The key players operating in the global NASH biomarkers market are Genfit SA, One Way Liver S.L., BioPredictive S.A.S, Siemens Heathcare Pvt. Ltd. (now Siemens Healthineers), Exalenz Biosciences Ltd., Prometheus Laboratories Corp. (part of Nestle Health Sciences), Quest Diagnostic Incorporated, and SNIBE diagnostics. 

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market      

Chapter 4. Market Overview
4.1. Introduction
     4.1.1. Marker Type Definition
     4.1.2. Industry Evolution / Developments
4.2. Market Overview
4.3. Key Market Indicators
4.4. Market Dynamics
     4.4.1. Drivers
     4.4.2. Restraints
     4.4.3. Opportunities
     4.4.4. Trends
4.5. Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast, 2016 – 2024
     4.5.1. Pricing – Actuals and Projections, 2016-2024 (US$)
     4.5.2. Market Revenue Projections (US$ Mn)
4.6. Porter’s Five Force Analysis
4.7. Value Chain Analysis
4.8. Market Outlook

Chapter 5. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By Marker Type
5.1. Introduction & Definition
5.2. Key Trends
5.3. Comparison Matrix
5.4. Market Size (US$ Mn) Forecast By Marker Type
     5.4.1. Serum Biomarkers
     5.4.2. Hepatic Fibrosis Markers
     5.4.3. Oxidative Stress Markers
     5.4.4. Apoptosis Markers
     5.4.5. Others (miRNA, carbon isotopes)
5.5. Market Attractiveness By Marker Type  

Chapter 6. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By End User
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Key Trends
6.4. Comparison Matrix
6.5. Market Size (US$ Mn) Forecast By End User
     6.5.1. Contract Research Organizations / pharmaceutical industry
     6.5.2. Academic Research Institute
     6.5.3. Hospitals
     6.5.4. Diagnostic Laboratories
6.6. Market Attractiveness By End User  

Chapter 7. Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Key Trends
7.3. Market Size (US$ Mn) Forecast By Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific 
     7.3.5. Middle East and Africa
7.4. Market Attractiveness By Region

Chapter 8. North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
8.1. Introduction
8.2. Key Findings / Developments
8.3. Key Trends
8.4. Market Size (US$ Mn) Forecast By Marker Type
     8.4.1. Serum Biomarkers
     8.4.2. Hepatic Fibrosis Markers
     8.4.3. Oxidative Stress Markers
     8.4.4. Apoptosis Markers
     8.4.5. Others (miRNA, carbon isotopes)
8.5. Market Size (US$ Mn) Forecast By End User
     8.5.1. Contract Research Organizations / pharmaceutical industry
     8.5.2. Academic Research Institute
     8.5.3. Hospitals
     8.5.4. Diagnostic Laboratories
8.6. Market Size (US$ Mn) Forecast, By Country
     8.6.1. U.S.
     8.6.2. Canada
8.7. Market Attractiveness Analysis 
     8.7.1. By Marker Type
     8.7.2. By End User
     8.7.3. By Country

Chapter 9. Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings / Developments
9.3. Key Trends
9.4. Market Size (US$ Mn) Forecast By Marker Type
     9.4.1. Serum Biomarkers
     9.4.2. Hepatic Fibrosis Markers
     9.4.3. Oxidative Stress Markers
     9.4.4. Apoptosis Markers
     9.4.5. Others (miRNA, carbon isotopes)
9.5. Market Size (US$ Mn) Forecast By End User
     9.5.1. Contract Research Organizations / pharmaceutical industry
     9.5.2. Academic Research Institute
     9.5.3. Hospitals
     9.5.4. Diagnostic Laboratories
9.6. Market Size (US$ Mn) Forecast, By Country
     9.6.1. U.K.
     9.6.2. France
     9.6.3. Germany
     9.6.4. Spain
     9.6.5. Rest of Europe
9.7. Market Attractiveness Analysis 
     9.7.1. By Marker Type
     9.7.2. By End User
     9.7.3. By Country 

Chapter 10. Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings / Developments
10.3. Key Trends
10.4. Market Size (US$ Mn) Forecast By Marker Type
     10.4.1. Serum Biomarkers
     10.4.2. Hepatic Fibrosis Markers
     10.4.3. Oxidative Stress Markers
     10.4.4. Apoptosis Markers
     10.4.5. Others (miRNA, carbon isotopes)
10.5. Market Size (US$ Mn) Forecast By End User
     10.5.1. Contract Research Organizations / pharmaceutical industry
     10.5.2. Academic Research Institute
     10.5.3. Hospitals
     10.5.4. Diagnostic Laboratories
10.6. Market Size (US$ Mn) Forecast, By Country
     10.6.1. Japan
     10.6.2. China
     10.6.3. India
     10.6.4. Rest of APAC
10.7. Market Attractiveness Analysis 
     10.7.1. By Marker Type
     10.7.2. By End User
     10.7.3. By Country 

Chapter 11. Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market  Analysis and Forecast
11.1. Introduction
11.2. Key Findings / Developments
11.3. Key Trends
11.4. Market Size (US$ Mn) Forecast By Marker Type
     11.4.1. Serum Biomarkers
     11.4.2. Hepatic Fibrosis Markers
     11.4.3. Oxidative Stress Markers
     11.4.4. Apoptosis Markers
     11.4.5. Others (miRNA, carbon isotopes)
11.5. Market Size (US$ Mn) Forecast By End User
     11.5.1. Contract Research Organizations / pharmaceutical industry
     11.5.2. Academic Research Institute
     11.5.3. Hospitals
     11.5.4. Diagnostic Laboratories
11.6. Market Size (US$ Mn) Forecast, By Country
     11.6.1. Brazil
     11.6.2. Mexico
     11.6.3. Argentina
     11.6.4. Rest of Latin America
11.7. Market Attractiveness Analysis 
     11.7.1. By Marker Type
     11.7.2. By End User
     11.7.3. By Country 

Chapter 12. Middle East & Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market  Analysis and Forecast
12.1. Introduction
12.2. Key Findings / Developments
12.3. Key Trends
12.4. Market Size (US$ Mn) Forecast By Marker Type
     12.4.1. Serum Biomarkers
     12.4.2. Hepatic Fibrosis Markers
     12.4.3. Oxidative Stress Markers
     12.4.4. Apoptosis Markers
     12.4.5. Others (miRNA, carbon isotopes)
12.5. Market Size (US$ Mn) Forecast By End User
     12.5.1. Contract Research Organizations / pharmaceutical industry
     12.5.2. Academic Research Institute
     12.5.3. Hospitals
     12.5.4. Diagnostic Laboratories
12.6. Market Size (US$ Mn) Forecast, By Country
     12.6.1. South Africa
     12.6.2. GCC Countries
     12.6.3. Rest of MEA
12.7. Market Attractiveness Analysis 
     12.7.1. By Marker Type
     12.7.2. By End User
     12.7.3. By Country 

Chapter 13. Competition Landscape
13.1. Nonalcoholic Steatohepatitis (NASH) Biomarkers Market – Competition Matrix (By Tier and Size of companies) (2015)
13.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
     13.2.1. BioPredictive S.A.S
             13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
             13.2.1.2. Product Portfolio
             13.2.1.3. SWOT Analysis
             13.2.1.4. Strategic Overview
     13.2.2. One Way Liver S.L.
             13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
             13.2.2.2. Product Portfolio
             13.2.2.3. SWOT Analysis
             13.2.2.4. Strategic Overview
     13.2.3. Genfit SA
             13.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
             13.2.3.2. Product Portfolio
             13.2.3.3. SWOT Analysis
             13.2.3.4. Financial Overview
             13.2.3.5. Strategic Overview
     13.2.4. Quest Diagnostics Incorporated
             13.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
             13.2.4.2. Product Portfolio
             13.2.4.3. SWOT Analysis
             13.2.4.4. Financial Overview
             13.2.4.5. Strategic Overview
     13.2.5. Prometheus Laboratories Inc. (Part of Nestle Health Sciences)
             13.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
             13.2.5.2. Product Portfolio
             13.2.5.3. SWOT Analysis
             13.2.5.4. Financial Overview
             13.2.5.5. Strategic Overview
     13.2.6. Siemens Healthcare Private Ltd. (now Siemens Healthineers)
             13.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
             13.2.6.2. Product Portfolio
             13.2.6.3. SWOT Analysis
             13.2.6.4. Financial Overview
             13.2.6.5. Strategic Overview
     13.2.7. Shenzhen New Industries Biomedical Engineering Co. Ltd. (SNIBE Diagnostics)
             13.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
             13.2.7.2. Product Portfolio
             13.2.7.3. SWOT Analysis
             13.2.7.4. Financial Overview
             13.2.7.5. Strategic Overview
     13.2.8. Exalenz Biosciences Ltd.
             13.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
             13.2.8.2. Product Portfolio
             13.2.8.3. SWOT Analysis
             13.2.8.4. Financial Overview
             13.2.8.5. Strategic Overview

Chapter 14. Key Take Away

List of Figures

Figure 01: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
Figure 02: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Market Type, 2017 and 2024
Figure 03: Global Serum Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 04: Global Hepatic Fibrosis Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015-2024
Figure 05: Global Apoptosis Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 06: Global Oxidative Stress Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 07: Global other Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 08: Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 09: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End-user, 2017 and 2024
Figure 10: Global CRO / Pharmaceutical Industry Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 11: Global Academic Research Institute Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 12: Global Hospital Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 13: Global Diagnostic Laboratories Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2024
Figure 14: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End-user
Figure 15: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Region, 2017 and 2024 
Figure 16: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Region
Figure 17: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Marker Type, 2017 and2024
Figure 18: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End User, 2017 and 2024
Figure 19: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 20: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Country
Figure 21: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country, 2017 and 2024
Figure 22: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 23: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End User
Figure 24: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Marker Type, 2017 and 2024
Figure 25: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End User, 2017 and 2024
Figure 26: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 27: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Country
Figure 28: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country, 2017 and 2024
Figure 29: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 30: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End User
Figure 31: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Marker Type, 2017 and 2024 
Figure 32: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End User, 2017 and 2024
Figure 33: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 34: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Country
Figure 35: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country, 2017 and 2024
Figure 36: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 37: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End User
Figure 38: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Marker Type, 2017 and2024
Figure 39: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End User, 2017 and 2024
Figure 40: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024
Figure 41: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Country
Figure 42: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country, 2017 and 2024
Figure 43: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 44: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End User
Figure 45: Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Marker Type, 2017 and 2024
Figure 46: Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by End User, 2017 and 2024
Figure 47: Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2024 
Figure 48: Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Country
Figure 49: MEA Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Value Share Analysis, by Country, 2017 and 2024
Figure 50: MEA Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by Marker Type
Figure 51: MEA Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness Analysis, by End User

List of Tables

Table 01: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Marker Type, 2015–2024
Table 02: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by End-user, 2015–2024
Table 03: Global Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Region,
Table 04: North America Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by Marker Type, 2015–2024
Table 05: North America Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by End User, 2015–2024
Table 06: North America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Country,
Table 07: Europe Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by Marker Type, 2015–2024
Table 08: Europe Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by End User, 2015–2024
Table 09: Europe Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Country, 2015–2024
Table 10: Asia Pacific Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by Marker Type, 2015–2024
Table 11: Asia Pacific Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by End User, 2015–2024
Table 12: Asia Pacific Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Country, 2015–2024
Table 13: Latin America Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by Marker Type, 2015–2024
Table 14: Latin America Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by End User, 2015–2024
Table 15: Latin America Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Country, 2015–2024
Table 16: Middle East and Africa Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by Marker Type, 
Table 17: Middle East and Africa Nonalcoholic Steatohepatitis Market Size (US$ Mn) Forecast, by End User, 2015–2024
Table 18: Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Country, 2015–2024

Global Non-alcoholic Steatohepatitis Biomarker Market: Overview

Non-alcoholic steatohepatitis (NASH) is liver disease which is categorized under the spectrum of non-alcoholic fatty liver disease (NAFLD). NASH is an advanced form of NAFLD where the liver inflammation occurs owing to fat deposition in liver. The fat accumulation may be induced by genetic abnormalities, metabolic dysfunction, drug induced damages, etc. Untreated and advanced NASH is one of the major reason for liver cirrhosis and sever liver damage such as liver failure. Presently three distinct method are used for diagnosis and monitoring of NASH, those are biopsy derived histopathology, imaging tools like transient elastography (TE), magnetic resonance imaging (MRI), etc., and in vitro diagnostic using biomarkers. As per the World Gastroenterology Organization It is estimated that around 20% to 30% of world population is affected with NAFLD.

Global Non-alcoholic Steatohepatitis Biomarker Market: Drivers and Trends

Increasing prevalence of NASH associated conditions like obesity and diabetes are expected to drive the growth of NASH biomarkers market. According to Deutsche Bank around 45 million people are anticipated to be affected by NASH in the U.S. and EU5 countries by 2025. Also there are many industry players investing on development of NASH therapeutic drugs, and most of them are in phase II or III of clinical trials. Their requirement of non-invasive diagnostic tools for monitoring their drug effectiveness is expected to drive the growth for NASH biomarkers market over the forecasted period. Biomarkers based NASH diagnostic tests are proposed to be at lower cost and non-invasive which is expected to make them a preferred tool for NASH diagnosis over invasive liver biopsy and costly imaging techniques. Ongoing research in discovery and development of novel NASH biomarkers is expected to drive the growth of NASH biomarkers market. However presently available NASH biomarkers are less accurate and have little efficacy which makes their usage limited. Also their results are overlapping with other metabolic disorders which is anticipated to restrain the growth of NASH biomarkers market.

Global Non-alcoholic Steatohepatitis Biomarker Market: Segmentation

Based on the marker type the global non-alcoholic steatohepatitis biomarkers market is segmented in to five segments viz. serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others. Serum biomarkers are expected to dominate the global NASH biomarkers market in the first half of the forecasted period. Owing to their indirect relation with NASH and other limitations they are expected to lose their market share in the second half of forecasted period. The Hepatic fibrosis markers are expected to grow exponentially over the forecasted period owing to their more accuracy and efficacy. This marker type segment is expected to hold the largest share of NASH biomarkers market by 2024. With expected launch of new diagnostic tools by Genfit SA and Exalenz Biosciences Ltd. the other markers segment is expected to have an exponential growth over the forecasted period.

Based on end-user, the global non-alcoholic steatohepatitis biomarkers market has been segmented into contract research organization (CRO) & pharmaceutical industry, academic research institutes, hospitals, and diagnostic laboratories. Owing to the requirement of non-invasive diagnostic tools for routine monitoring of drug therapy effectiveness during the clinical trial of drug candidates, the CRO & pharmaceutical industry end-user segment is expected to have a moderate growth over the forecasted period. However towards the end of forecasted period this segment is expected to be superseded by hospital and diagnostic laboratories end-user segment. With expected launch of companion diagnostic tests along with NASH therapeutic drugs the hospitals and diagnostic laboratories segments of end-user are expected to witness an exponential growth over forecasted period. The hospital end-user segment is expected to grow at CAGR of 36.6% while diagnostic laboratories segment is expected to grow at CAGR of 37.0% over the forecasted period.

Global Non-alcoholic Steatohepatitis Biomarker Market: Regional Outlook

Geographically, the non-alcoholic steatohepatitis biomarkers market has been segmented into five regions: North America, Latin America, Europe, Asia Pacific and Middle East and Africa. These regions have been further segmented by marker type and end-user segments. The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global non-alcoholic steatohepatitis biomarkers market.

Key Players Mentioned in this Report are:

The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include One Way Liver S.L., BioPredictive S.A.S, Siemens Heathcare Pvt. Ltd. (now Siemens Healthineers), Genfit SA, Exalenz Biosciences Ltd., Quest Diagnostic Incorporated, Prometheus Laboratories Corp. (part of Nestle Health Sciences) and SNIBE diagnostics.

The global non-alcoholic steatohepatitis biomarkers market has been segmented as follows:

Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, by Marker Type

  • Serum Biomarkers
  • Hepatic Fibrosis Biomarkers
  • Apoptosis Biomarkers
  • Oxidative Stress Biomarkers
  • Others

Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market, by End-User

  • Contract Research Organization(CRO) & Pharmaceutical Industry
  • Academic Research Institutes
  • Hospitals
  • Diagnostic Laboratories


 
 
Back To Top